期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 21, 期 2, 页码 179-185出版社
WILEY
DOI: 10.1111/j.1365-2036.2005.02317.x
关键词
-
Background: The C-13-methacetin breath test enables the quantitative evaluation of the cytochrome P450-dependent liver function. Aim: To find out whether this breath test is sensitive in noncirrhotic patients also with chronic hepatitis C in early stages of fibrosis. Methods: Sixty-one healthy controls and 81 patients with chronic hepatitis C underwent a C-13-methacetin breath test. In all patients, a liver biopsy was performed. The liver histology was classified according to the histology activity index-Knodell score. Results: Delta over baseline values of the patients at 15 min significantly differed from controls (19.2+/-9.2parts per thousand vs. 24.1+/-5.7parts per thousand; P<0.003). The cumulative recovery after 30 min in patients was 11.4+/-4.8% and in healthy controls 13.8+/-2.8% (P<0.002). However, patients with early fibrosis (histology activity index IVB) did not differ in delta over baseline values of the patients at 15 min (23.2+/-7.9parts per thousand vs. 22.6+/-7.2parts per thousand; P=0.61) or cumulative recovery (13.6+/-3.7% vs. 13.2+/-3.8%; P=0.45) from patients with more advanced fibrosis (histology activity index IVC). Patients with clinically nonsymptomatic cirrhosis (histology activity index IVD; Child A) metabolized C-13-methacetin to a significantly lesser extent (delta over baseline values of the patients at 15 min: 8.3+/-4.9parts per thousand; P<0.005 and cumulative recovery after 30 min: 5.6+/-3.2%; P<0.003). The C-13-methacetin breath test identified cirrhotic patients with 95.0% sensitivity and 96.7% specificity. Conclusion: The non-invasive C-13-methacetin breath test reliably distinguishes between early cirrhotic (Child A) and noncirrhotic patients, but fails to detect early stages of fibrosis in patients with chronic hepatitis C.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据